Market Newsdesk

J.P. Morgan Online Investing Raises the Bar on New Account Rewards

Offers clients up to $500 when they refer friends for Online Self-Directed Investing

New clients to receive up to $625 bonus

NEW YORK–(BUSINESS WIRE)–
J.P. Morgan Wealth Management is upping its rewards for new and existing J.P. Morgan Self-Directed Investing clients to promote commission-free unlimited online trading.

Existing customers will receive a $50 bonus deposited to their account for each person they recommend who opens a Self-Directed Investing account through the refer-a-friend link. Existing customers can receive up to a total of a $500 credit in their account a year for the referrals. New clients will have the opportunity to earn up to $625 credited to their account when they open a J.P. Morgan Self-Directed Investing account.

“Growing your wealth on your own is such an empowering experience. When you reach that personal milestone, you want to share your story with your friends and network,” said Paul Vienick, Head of Online Investing at J.P. Morgan Wealth Management. “Investors who use the award-winning Chase app to trade are increasingly happier with their experience as we expand the tools we offer, and we want our clients to share that. There’s no better endorsement than one from someone you know and trust.”

With J.P. Morgan Self-Directed Investing, clients can choose from thousands of stocks, mutual funds and options¹ to make unlimited commission-free trades online or through the Chase app. Clients can take advantage of personalized market news as well as portfolio builders and watchlists to help choose investments that fit their priorities right from their mobile device. They can take charge of their finances all in one place and easily move cash from a Chase checking or savings account to invest. As part of a solid global financial institution, clients also have access to top-ranked J.P. Morgan research to make informed investment decisions on their terms to help them build wealth over time.

New customers can receive $125 for Self-Directed Investing accounts funded with $25,000, $300 for accounts with at least $100,000 and a $625 reward for accounts funded with $250,000 or more. Funds must come from a non-Chase or non-J.P. Morgan account. New customers can redeem the offer through this link.

J.P. Morgan Online Investing, launched in 2018, is a secure and reliable platform able to weather volatile markets and provide investors an easy-to-use trading experience. The firm continues to heavily invest in technology, research and products to better serve and protect clients.

Self-directed investing is becoming more popular with customers who are increasingly engaging with their banks via mobile apps and digitally supported tools. You can read more about this trend in: The rise of self-directed investing

About J.P. Morgan Wealth Management

J.P. Morgan Wealth Management is the U.S. wealth management business of JPMorgan Chase & Co., a leading global financial services firm with assets of $3.7 trillion and operations worldwide. J.P. Morgan Wealth Management has ~5,000 advisors and more than $700 billion of assets under supervision. Clients can choose how and where they want to invest. They can do it digitally, remotely, or in person by meeting with a J.P. Morgan Advisor in one of our 4,800 Chase branches throughout the U.S., or in one of our 21 offices. For more information, go to www.jpmorganwealthmanagement.com and follow @JPMWealth on Twitter. To learn more about J.P. Morgan Online Investing, visit https://www.chase.com/personal/investments/online-investing

_____________________

¹ Options trading is subject to approval.

Refer-a-friend offer details:

Referral bonus is available to eligible J.P. Morgan Self-Directed Investing account holders approximately 30 days after account opening. To receive the $50 Refer-A-Friend bonus: 1) Refer your family and friends to open and fund a J.P. Morgan Self-Directed Investing account through this referral site; 2) Referred candidate must open a new eligible J.P. Morgan Self-Directed Investing account (General Investment only) and fund a minimum of $200 of new money in cash or securities within 45 days of their coupon enrollment; AND 3) After your referred candidate has opened and funded their J.P. Morgan Self-Directed Investing account, we’ll deposit the $50 bonus into your J.P. Morgan Self-Directed Investing account within 15 days, provided both the customer and referral accounts are not closed or restricted at the time of payout. You can receive up to 10 referral bonus deposits (totaling $500) per calendar year.

*Bonuses may be considered income and may be reportable to you and the IRS on Form 1099-MISC (“Miscellaneous information”) or Form 1042-S (“Foreign Person’s U.S. Source Income Subject to Withholding”) if applicable.

Employees of JPMorgan Chase & Co. and its affiliates are not eligible for the Refer-A-Friend Program.

Refer-A-Friend program is available for the following account types: New J.P. Morgan Self-Directed Investing account (General Investment only). This offer does not apply to Self-Directed Investing Traditional IRA or Roth IRA accounts, J.P. Morgan Automated Investing or any account opened with a J.P. Morgan Advisor.

New customer offer details:

Offer eligibility and restrictions: *Cash promotion is limited to one per customer and can only be applied to one new J.P. Morgan Self-Directed Investing account (General Investment only). To enroll in the up to $625 offer, you must open an account through this page. This offer does not apply to Self-Directed Investing Traditional IRA or Roth IRA accounts, J.P. Morgan Automated Investing or any account opened with a J.P. Morgan Advisor. To receive the cash bonus:

1) Customers must open and fund a new eligible J.P. Morgan Self-Directed Investing account with new money of $25,000 or more in cash or securities from a non-Chase or non-J.P. Morgan account and the qualifying new money cannot be existing deposits, funds or securities held by you at JP Morgan Chase or its affiliates. New money must be transferred within 45 days of coupon enrollment date.

2) At day 45 from coupon enrollment, the bonus tier will be determined in the following manner:

New money inflows		Cash Bonus
$25,000-$99,999		$125
$100,000-$249,999		$300
$250,000+		$625

3) The new money balance must be maintained in the account for at least 90 days from the coupon enrollment (losses due to trading or market fluctuation will not be taken into account). Cash bonus will be credited to the account within 15 days of these requirements being met. You can only participate in one Chase Private Client Checking^SM, Chase Sapphire^SM Checking or J.P. Morgan Self-Directed Investing new money bonus in a 12 month period from the last bonus enrollment date. Coupon is good for one time use and only one bonus per account. Account types and other restrictions apply. Offer terms are subject to change and/or termination without advance notice. The value of the cash award may be considered income, and we may be required to send you, and file with the IRS, a Form 1099-MISC (“Miscellaneous Information”), or a Form 1042-S (“Foreign Person‘s U.S. Source Income Subject to Withholding”) if applicable. You are responsible for any tax liability associated with the award. Please consult your own tax advisor if you have any questions about your personal tax situation.

INVESTMENT AND INSURANCE PRODUCTS ARE:

• NOT FDIC INSURED • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY • NOT A DEPOSIT OR

OTHER OBLIGATION OF, OR GUARANTEED BY, JPMORGAN CHASE BANK, N.A. OR ANY OF ITS AFFILIATES

• SUBJECT TO INVESTMENT RISKS, INCLUDING POSSIBLE LOSS OF THE PRINCIPAL AMOUNT INVESTED

J.P. Morgan Wealth Management is a business of JPMorgan Chase & Co., which offers investment products and services through J.P. Morgan Securities LLC (JPMS), a registered broker-dealer and investment advisor, member FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. Certain custody and other services are provided by JPMorgan Chase Bank, N.A. (JPMCB). JPMS, CIA and JPMCB are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

© 2022 JPMorgan Chase & Co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005662/en/

Media Contact

Michaela Nichols

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Mobile/Wireless Technology Finance Security Banking Other Technology Professional Services Internet Data Management Other Professional Services

MEDIA:

Posted on January 19, 2022 9:32 am

India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors

India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors

POTOMAC, Md.–(BUSINESS WIRE)–
India Globalization Capital, Inc. (NYSE American: IGC) is excited to announce that the Board has appointed former Congressman Jim Moran (“Congressman Moran”) as an independent Director. IGC is delighted to welcome Congressman Moran to its Board of Directors.

Congressman Moran served Virginia’s 8^th Congressional District for 24 years, where he was known as a “Problem Solver.” Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance and Budget committees. He played a leadership role in the areas of defense, health, and the environment.

During his 24 years in Congress, Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility. He rose to senior leadership on the Appropriations Committee enabling him to bring billions of dollars into his Northern Virginia communities of Alexandria, Arlington, and Fairfax Counties. Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic clients in the defense, technology, entertainment and international diplomacy sectors. He also serves in leadership roles for several non-profit foundations and is also a member of the Government Blockchain Association.

Congressman Moran introduced the AUTISM Educators Act in 2012, which funded partnerships between public schools and higher education and non-profit organizations to promote teaching skills for educators working with high functioning autism students. He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives.

Congressman Moran received a Master’s Degree in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelors in Economics from the College of the Holy Cross.

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease. We look forward to his guidance in helping us bring new, THC-based investigational medications into FDA approved clinical trials.

Upon his election to the IGC Board of Directors, Congressman Moran made the following statement: “I am excited to have an opportunity to play a role in the growth of an organization dedicated to scientific and medical research targeted especially at reducing the pain and loss suffered from Alzheimer’s disease. While I am aware of the medicinal benefits that marijuana can offer some individuals, IGC is engaged in clinical research trials that employ hemp-sourced cannabinoids to facilitate better brain functioning in subjects that may be vulnerable to Alzheimer’s. If such promising research is successful, it may have implications for advances in the understanding of other central nervous disorders.”

About IGC:

India Globalization Capital, Inc. (IGC), headquartered in Maryland, engages in the development of cannabinoid-based therapies for healthcare applications. IGC recently completed the first safety and tolerability clinical trial to treat symptoms of Alzheimer’s patients using a THC-based investigational new drug. The Company also operates an infrastructure business based in India. www.igcinc.us, www.igcpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118006191/en/

Claudia Grimaldi

[email protected]

Phone: 301-983-0998

KEYWORDS: United States North America Maryland Virginia District of Columbia

INDUSTRY KEYWORDS: Alternative Medicine Health FDA General Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo

Alkaline88® Leads Fourth Quarter Growth for Enhanced Water Brands

New Nielsen data shows that Alkaline88 was the fastest-growing top-ten value-added brand.

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–
The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”), the country’s largest independent alkaline company and the Clean Beverage^® company, today announced the results of Nielsen data for the 13-week period ending January 1, 2022. Per the report, Alkaline88^® was the fastest-growing top-ten value-added water in the country in dollar volume percentage. Across Nielsen’s All Outlets Combined (“xAOC”), Alkaline88 outpaced the rest of the top-ten brands and grew at rates more than double the overall category average. Year-over-year sales growth was 46.4% in xAOC, compared to a category average of 19.3%.

Other highlights from the Nielsen data for Value-Added Water for the 13 weeks ending January 1, 2022 include:

• Deliciously Smooth™ Alkaline88^® is the fastest growing top-ten value-added water brand by dollar volume in the whole country.
• Alkaline88 is the 9^th largest brand in xAOC and the 8^th largest in Grocery.
• Alkaline88 had a 25% increase in market share compared to the same period a year earlier.
• Alkaline88 is the second fastest-growing top-ten brand in unit volume.
• The Alkaline88 1-Gallon is now the 6^th best-selling SKU in the category.
• Alkaline88’s promotional dollar spend was 27% less than the average of the other top-ten non-flavored water brands.

“The Nielsen data for the last quarter clearly indicates that Alkaline88 continues to accelerate sales,” said Ricky Wright, President and CEO of The Alkaline Water Company. “What makes this so impressive is that October, November, and December have historically been our slowest months. We know that we’ve benefitted from the activation of TV commercials featuring Shaquille O’Neal in limited test markets during this time and consumers also began to see our products in 587 Sam’s Clubs throughout the country. Our brand loyalty has been evident in sales in our largest legacy accounts, which continue to grow double digits. Some of the largest growth has been seen in national retail leaders like Wal-Mart, CVS, Kroger, Rite-Aid, and Safeway/Albertsons. We also continue to outperform our competitors in the all-important Natural Food channel.

“We’re able to support 46.6% growth thanks to the strategic supply chain initiatives we’ve undertaken over the past two years. As a result of these, we’ve had almost no supply chain disruption. These initiatives include opening multiple new copackers geographically distributed across the country and redundantly sourcing raw materials here in the United States. With the continued growth in our existing banners and the addition of new retailers in upcoming quarters, we believe we’ll continue to be one of the fastest-growing top-ten brands and the largest independent alkaline water company in the country.”

About The Alkaline Water Company:

The Alkaline Water Company is The Clean Beverage Company™ making a difference in the water you drink and the world we share.

Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts our trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, The Alkaline Water Company created the A88 Infused Beverage Division in 2018 to meet consumer demand for flavor-infused products under the A88 Infused™ brand. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for the Alkaline88® and A88 Infused™ brands.

To purchase The Alkaline Water Company’s products online, visit us at www.alkaline88.com.

To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect with us on Facebook, Twitter, Instagram, or LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, that the Company believes that with the continued growth in its existing banners and the addition of new retailers in upcoming quarters, it will continue to be one of the fastest-growing top-ten brands and the largest independent alkaline water company in the country.

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005304/en/

The Alkaline Water Company Inc.

Jeff Wright

Director of Investor Relations

866-242-0240

[email protected]

Media

Jessica Starman

888-461-2233

[email protected]

KEYWORDS: United States North America Canada Arizona

INDUSTRY KEYWORDS: Supermarket Retail Convenience Store Food/Beverage

MEDIA:

Logo

PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics

Partnership enables comprehensive clinical information to deliver optimal patient care

ST. LOUIS–(BUSINESS WIRE)–
PierianDx, the global leader in clinical genomics knowledge, today announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGS™ genomic test, a blood-based tumor profiling test to detect actionable mutations in patients with non-small cell lung cancer (NSCLC). Biodesix (Nasdaq: BDSX) will use the PierianDx platform to provide clear, up-to-date clinical interpretations for mutations detected by the GeneStrat NGS test as part of patient test results used by physicians to help inform a personalized treatment strategy and facilitate monitoring in lung cancer.

The GeneStrat NGS test is a key part of the IQLung™ testing strategy, designed to measure tumor-specific mutations and patient immune profiles with results in an unprecedented 72 hours so that physicians can assess overall prognosis and personalize treatment plans. The IQLung strategy uses genomic profiling to detect actionable mutations in lung cancer, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner.

The GeneStrat NGS test data will be analyzed and interpreted using the most current therapy approvals and oncology guideline recommendations and delivered in a physician-ready report. The technology is backed by a comprehensive clinical knowledgebase and adaptive learning algorithms that take disparate inputs and translate them into concise interpretations with supporting evidence. As a result, characteristics of patient variants, even though rare or novel, are leveraged to present the most optimal treatment possibilities.

“We are helping to meet an unmet need in the continuum of care for lung cancer,” said Scott Hutton, CEO of Biodesix. “Partnering with PierianDx not only helps to deliver rapid results to physicians, but it also gives them information that can be easily interpreted and actioned, supporting them in providing precision care for their patients.”

“We are thrilled to provide our interpretation technology to support the outstanding testing solution from Biodesix to treat patients with lung cancer,” states Mark McDonough, CEO of PierianDx. “We are committed to democratizing clinical genomics globally and this partnership with Biodesix supports our vision to broaden access to genomic testing and provide precision care to patients everywhere.”

About PierianDx

PierianDx is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care. We believe in the potential of genomics to transform human health and are working to ensure that communities anywhere can experience the benefits. With advanced interpretation technology connected to the most comprehensive genomic knowledgebase, PierianDx empowers providers with genomic insights to fulfill the promise of precision care. For more information, visit www.pieriandx.com.

About Biodesix

Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 16, 2021, or subsequent quarterly reports on Form 10-Q during 2021, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005186/en/

Lisa Owen

[email protected]

KEYWORDS: Missouri United States North America

INDUSTRY KEYWORDS: Data Management Medical Supplies Biotechnology Technology Health Oncology Other Technology Research Software Genetics Science

MEDIA:

Logo

Together with Matterport, Allseated is transforming the event planning industry with digital twins and virtual reality